Are we still on track for this?
In 2012 "B&L plans to release a new lens material with "unique properties not seen on the market today," Saunders said. The eye-care company also continues research and work on an experimental anti-inflammation drug Mapracorat."
If B+L is to maintain credibility for an IPO the CEO has to deliver on what he promised last October. One month down eleven more to go.
In 2012 "B&L plans to release a new lens material with "unique properties not seen on the market today," Saunders said. The eye-care company also continues research and work on an experimental anti-inflammation drug Mapracorat."
If B+L is to maintain credibility for an IPO the CEO has to deliver on what he promised last October. One month down eleven more to go.